Background: The third-generation tyrosine kinase inhibitor ponatinib has demonstrated high clinical efficacy in the setting of patients with resistant chronic phase chronic myeloid leukemia (CML), also inducing deep molecular responses. However, ponatinib-related cardiovascular toxicities make management challenging, especially of those patients with CML with previous cardiovascular comorbidities. Case Report: We report on the efficacy of ponatinib treatment used as fourth-line therapy in a 55-year-old woman affected by significant comorbidities (mainly cardiovascular) present before the diagnosis of CML. Ponatinib therapy induced a rapid and excellent clinical response, with the achievement of a durable deep molecular response that allowed us to propose a strategy of treatment discontinuation in order to reduce drug-related toxicities. Conclusion: A strategy of a treatment-free interval might represent a useful clinical tool in those patients with CML who achieve a durable deep molecular response but are also affected by significant comorbidities in order to minimize the risk of ponatinib-related toxicities. Copyright 2021, International Institute of Anticancer Research.
Background: The third-generation tyrosine kinase inhibitor ponatinib has demonstrated high clinical efficacy in the setting of patients with resistant chronic phase chronic myeloid leukemia (CML), also inducing deep molecular responses. However, ponatinib-related cardiovascular toxicities make management challenging, especially of those patients with CML with previous cardiovascular comorbidities. Case Report: We report on the efficacy of ponatinib treatment used as fourth-line therapy in a 55-year-old woman affected by significant comorbidities (mainly cardiovascular) present before the diagnosis of CML. Ponatinib therapy induced a rapid and excellent clinical response, with the achievement of a durable deep molecular response that allowed us to propose a strategy of treatment discontinuation in order to reduce drug-related toxicities. Conclusion: A strategy of a treatment-free interval might represent a useful clinical tool in those patients with CML who achieve a durable deep molecular response but are also affected by significant comorbidities in order to minimize the risk of ponatinib-related toxicities. Copyright 2021, International Institute of Anticancer Research.
Authors: Jorge E Cortes; Dong-Wook Kim; Javier Pinilla-Ibarz; Philipp D le Coutre; Ronald Paquette; Charles Chuah; Franck E Nicolini; Jane F Apperley; H Jean Khoury; Moshe Talpaz; Daniel J DeAngelo; Elisabetta Abruzzese; Delphine Rea; Michele Baccarani; Martin C Müller; Carlo Gambacorti-Passerini; Stephanie Lustgarten; Victor M Rivera; Frank G Haluska; François Guilhot; Michael W Deininger; Andreas Hochhaus; Timothy P Hughes; Neil P Shah; Hagop M Kantarjian Journal: Blood Date: 2018-03-22 Impact factor: 22.113
Authors: J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark Journal: Leukemia Date: 2016-04-28 Impact factor: 11.528